Bullous Pemphigoid

1. Clinical Overview

Summary

Bullous pemphigoid (BP) is the most common autoimmune subepidermal blistering disease, predominantly affecting individuals over 70 years of age. It is characterised by tense, dome-shaped blisters arising on erythematous, urticarial, or normal-appearing skin, caused by IgG autoantibodies directed against two hemidesmosomal proteins—BP180 (type XVII collagen) and BP230 (BPAG1)—at the dermal-epidermal junction.[1,2] The incidence of BP is increasing globally, attributed to population ageing, improved diagnostic recognition, and drug-induced cases (particularly DPP-4 inhibitors and immune checkpoint inhibitors).[3,4] Unlike pemphigus vulgaris, BP produces subepidermal blisters that are mechanically robust (tense), do not rupture easily, and the Nikolsky sign is negative. The disease causes substantial morbidity: severe pruritus profoundly impacts quality of life, extensive skin involvement risks fluid and protein loss, and elderly patients face high mortality (20-40% at 1 year) driven primarily by treatment complications and comorbidities rather than the disease itself.[5,6] First-line treatment is very potent topical corticosteroids (clobetasol propionate 0.05% applied to the whole body), which has superior efficacy and safety compared to oral corticosteroids.[7,8] Systemic immunosuppression is reserved for refractory or severe cases. Prognosis is favourable with appropriate treatment, with 50-70% achieving remission within 5 years, though relapse is common.[9]

Key Facts

• Epidemiology: Most common autoimmune blistering disease; incidence 6-43 per million/year globally, increasing over past 3 decades[3,10]
• Mean age of onset: 75-80 years; rare before 60 years
• Target antigens: BP180 (NC16A domain of type XVII collagen) and BP230 (BPAG1)
• Blister type: Tense, subepidermal (vs flaccid intraepidermal in pemphigus)
• Nikolsky sign: Negative (epidermis intact; dermal-epidermal separation in lamina lucida)
• Immunofluorescence: Linear IgG and C3 deposition at basement membrane zone (BMZ)
• First-line treatment: Very potent topical corticosteroids—clobetasol propionate 0.05% applied to entire body (20-40 g/day)[7,8]
• Landmark trial: BLISTER trial (2017) demonstrated topical clobetasol non-inferior to oral prednisolone with fewer adverse events[7]
• Prognosis: Chronic relapsing-remitting course; 50-70% achieve remission within 5 years; relapse rate 30-50%[9,11]
• Mortality: 1-year mortality 20-40% (age-matched controls ~10%); driven by treatment complications, infections, and comorbidities[5,6,12]
• Drug-induced BP: DPP-4 inhibitors (gliptins) carry 2-3× increased risk; also PD-1/PD-L1 checkpoint inhibitors in cancer patients[4,13,14]
• Quality of life: Severe pruritus is the most debilitating symptom, often preceding blisters by weeks to months[15]

Clinical Pearls

"Tense vs Flaccid Rule": Bullous pemphigoid has TENSE blisters (subepidermal; epidermis intact) while pemphigus has FLACCID blisters (intraepidermal; fragile roof). This clinical distinction is key before biopsy.

"The Urticarial Phase": BP often presents with pruritic urticarial plaques for weeks before blisters appear. Consider BP in elderly patients with new urticaria that doesn't respond to antihistamines.

"Topical First": The landmark BLISTER trial showed whole-body potent topical steroids are MORE effective than oral prednisolone with FEWER side effects. Topical is first-line even in extensive disease.

"Gliptin Alert": DPP-4 inhibitors (sitagliptin, linagliptin) are increasingly recognised as triggers of BP. Always check drug history and consider stopping the culprit.

"Beware the Comorbidity": BP patients are elderly with comorbidities. Mortality is driven by treatment complications (infections, falls, metabolic effects) more than the disease itself.

Why This Matters Clinically

Bullous pemphigoid is the most common autoimmune blistering disease encountered in clinical practice, yet it remains underdiagnosed, particularly in its pre-bullous (urticarial) phase.[16] The disease predominantly affects a vulnerable elderly population with multiple comorbidities, where diagnostic delay can lead to extensive skin involvement, secondary infection, and life-threatening complications. Severe pruritus—often the presenting symptom—profoundly impairs quality of life, disrupting sleep, mobility, and independence.[15] Accurate early diagnosis is critical: it avoids ineffective treatments (antihistamines for misdiagnosed "urticaria"), enables prompt initiation of evidence-based therapy (topical clobetasol), and prevents inappropriate use of high-dose systemic corticosteroids that carry substantial morbidity and mortality in the elderly.[7,8] Recognition of drug-induced BP (DPP-4 inhibitors, checkpoint inhibitors) can lead to disease resolution simply by withdrawing the culprit medication.[4,13] Optimal management balances disease control with minimising treatment toxicity: the paradigm shift from systemic to topical corticosteroids as first-line therapy has reduced adverse events without compromising efficacy.[7,8] Finally, understanding the high mortality risk (20-40% at 1 year) underscores the need for multidisciplinary care, vigilant monitoring for complications (infection, metabolic derangement, falls), and steroid-sparing strategies.[5,6,12]

---

2. Epidemiology

Incidence & Prevalence

Demographics

Risk Factors

---

3. Pathophysiology

Mechanism

Step 1: Loss of Immune Tolerance

• Genetic susceptibility: HLA-DQB1*0301 associated with BP in Caucasians; polymorphisms in cytokine genes (IL-4, IL-10)
• Immunosenescence: Age-related decline in regulatory T-cell function, thymic involution, chronic low-grade inflammation ("inflammageing")
• Environmental triggers: Drugs (DPP-4i, checkpoint inhibitors), UV radiation, physical trauma, burns, radiotherapy, infections
• Molecular mimicry: Possible cross-reactivity between microbial antigens and BP180/BP230
• Epitope spreading: Initial autoantibody response to one domain (e.g., BP180 NC16A) spreads to other epitopes[1,2,18]

Step 2: Autoantibody Production and Target Antigens

• BP180 (BPAG2, type XVII collagen):
  • 180 kDa transmembrane glycoprotein; major target in > 80% of cases
  • NC16A domain (non-collagenous 16A) is immunodominant epitope
  • Extracellular domain extends into lamina lucida and binds to laminin-332
  • Critical for hemidesmosome assembly and dermal-epidermal adhesion
• BP230 (BPAG1):
  • 230 kDa intracellular plakin protein
  • Plakin domain connects intermediate filaments to hemidesmosomal complex
  • Autoantibodies in 60-80% of cases; usually co-occur with anti-BP180
  • BP230-only antibodies rare (~5%); may present as non-bullous disease[19]
• Antibody characteristics:
  • Predominantly IgG4 and IgG1 subclasses
  • Autoantibody titres correlate with disease activity and predict relapse
  • Eosinophil-attracting antibodies contribute to inflammation[1,2,18]

Step 3: Immune Complex Formation and Complement Activation

• IgG autoantibodies bind to BP180/BP230 at basement membrane zone (BMZ)
• Immune complex deposition → complement activation (classical pathway)
• Generation of anaphylatoxins C3a and C5a → mast cell degranulation
• Release of histamine, tryptase, leukotrienes → vascular permeability, pruritus
• C5a recruits eosinophils and neutrophils to BMZ
• Formation of membrane attack complex (C5b-9) → keratinocyte damage[1,2,18]

Step 4: Inflammatory Cell Recruitment and Tissue Damage

• Eosinophils (hallmark):
  • Release cytotoxic granule proteins (major basic protein, eosinophil peroxidase)
  • Secrete matrix metalloproteinases (MMP-9) → degrade type IV collagen, laminin-332
  • Eosinophil extracellular traps (EETs) amplify inflammation
• Neutrophils:
  • Neutrophil elastase cleaves BP180 ectodomain
  • Release reactive oxygen species → oxidative tissue damage
• Mast cells:
  • Degranulation → histamine release → intense pruritus
  • Tryptase activates MMPs and recruits inflammatory cells
• Proteolytic cascade:
  • MMPs (MMP-2, MMP-9) and neutrophil elastase degrade hemidesmosomes
  • Loss of BP180/BP230 structural integrity
  • Disruption of keratinocyte-basement membrane adhesion[1,2,18]

Step 5: Subepidermal Blister Formation

• Proteolytic cleavage occurs in the lamina lucida (between plasma membrane of basal keratinocytes and lamina densa)
• Fluid accumulates in the subepidermal space
• Epidermis separates from dermis as an intact sheet → tense blisters
• Roof of blister contains intact epidermis (unlike intraepidermal blisters in pemphigus)
• Floor of blister is exposed dermis with inflammatory infiltrate
• Blisters heal without scarring (unless secondary infection causes dermal damage)[1,2,18]

Step 6: Clinical Disease Evolution

• Pre-bullous phase: Pruritus, urticarial plaques, eczematous lesions (weeks to months)
• Bullous phase: Tense blisters on inflamed or normal skin; eosinophil-rich infiltrate
• Erosive phase: Ruptured blisters → erosions with intact peripheral blister roofs
• Healing phase: Re-epithelialisation without scarring; post-inflammatory hyperpigmentation common
• Relapse: Fluctuating disease activity; antibody titres correlate with flares[9,11]

Molecular Pathogenesis: BP180 and BP230 Autoantibodies

BP180 (Type XVII Collagen):

• Structure: 180 kDa type II transmembrane collagen with intracellular, transmembrane, and extracellular domains
• NC16A domain: 45 amino acid non-collagenous region in extracellular domain; contains immunodominant epitopes
• Function: Forms trimers that anchor hemidesmosomes to laminin-332 in basement membrane
• Pathogenic mechanism: Anti-BP180 IgG (primarily IgG4) binding → complement activation → inflammatory cascade → proteolytic cleavage at lamina lucida
• Clinical correlation: BP180 antibody levels correlate with disease severity, treatment response, and relapse risk; quantitative ELISA used for monitoring[20]
• Epitope mapping: NC16A epitopes cluster in specific regions; different epitopes may predict clinical phenotype (bullous vs non-bullous)[1,18]

BP230 (BPAG1-e):

• Structure: 230 kDa cytoplasmic plakin protein; part of dystonin family
• Function: Links intermediate filaments (keratin) to hemidesmosomal plaque via intracellular domain
• Pathogenic role: Less clear than BP180; BP230 antibodies alone rarely cause disease; may contribute via intracellular mechanisms
• Isolated BP230 antibodies: 5% of BP cases; often present as non-bullous pemphigoid with pruritic dermatosis[19]
• Dual reactivity: Most BP patients have antibodies against both BP180 and BP230; presence of both may indicate more severe disease
• Monitoring utility: BP230 ELISA less sensitive than BP180 NC16A ELISA; mainly used in BP180-negative cases[2,20]

Antibody Dynamics and Disease Activity:

• Baseline titres: High BP180 NC16A IgG levels (> 150 U/mL) correlate with extensive disease
• Treatment response: Antibody titres decrease with successful treatment; lag behind clinical improvement by 2-4 weeks
• Relapse prediction: Rising titres precede clinical relapse by 2-8 weeks; serial monitoring identifies subclinical relapse[20]
• Remission: Persistent low/undetectable antibodies for > 6 months associated with sustained remission
• IgG subclasses: IgG4 predominates (pathogenic); IgG1 also present; IgG4:IgG1 ratio may predict treatment response[1,18]

Key Differences from Pemphigus

Non-Bullous Pemphigoid

Overview: 10-20% of BP cases present without blisters (non-bullous pemphigoid, NBP), making diagnosis challenging. This variant is characterised by pruritus and urticarial, eczematous, or papular lesions without overt blistering.[16]

Clinical Features:

• Severe pruritus (universal feature)
• Urticarial plaques (most common)
• Eczematous patches
• Excoriated papules and nodules (prurigo-like)
• Erythematous patches
• Duration: Weeks to months before blisters appear (or blisters may never develop)

Diagnosis:

• Direct immunofluorescence (DIF): Linear IgG/C3 at BMZ (diagnostic)
• BP180/BP230 ELISA: Positive serology
• Histology: Eosinophil-rich dermal infiltrate, papillary oedema; no frank blister
• High index of suspicion required: Elderly patient + refractory "urticaria" or "eczema" + severe pruritus → consider NBP[16]

Treatment:

• Similar to bullous BP: Potent topical steroids
• May respond to doxycycline + nicotinamide for mild cases
• Often progresses to bullous phase if untreated

Clinical Pearl: NBP is frequently misdiagnosed as urticaria, eczema, or prurigo. Consider BP in any elderly patient with refractory pruritic dermatosis not responding to conventional therapy. DIF is key to diagnosis.[16]

Drug-Induced BP

Clinical Implications of Drug-Induced BP:

• Withdrawal of culprit drug may lead to faster disease resolution and reduced treatment requirements[13]
• DPP-4 inhibitor-induced BP: 30-50% achieve remission with drug cessation alone within 3-6 months
• Checkpoint inhibitor-induced BP: Often requires continuation of cancer therapy; concurrent immunosuppression needed
• Always obtain detailed drug history including supplements, over-the-counter medications, and recent vaccinations[4,13,14]

---

4. Clinical Presentation

Prodromal Phase (Pre-Bullous)

Bullous Phase

Distribution Pattern

Red Flags

[!CAUTION] Red Flags — Require Urgent Assessment:

• Extensive disease (> 20% BSA) with fluid/protein loss
• Signs of cellulitis or secondary bacterial infection
• Elderly patient with poor nutrition or multiple comorbidities
• Mucosal involvement (consider pemphigus)
• Known immunosuppression
• New-onset in patient on DPP-4 inhibitor or checkpoint inhibitor (drug-induced BP)

---

5. Clinical Examination

Structured Approach

General Inspection:

• Overall condition and frailty
• Nutritional status
• Signs of sepsis or systemic illness

Skin Examination:

• Distribution and extent of blisters (calculate %BSA)
• Character of blisters (tense vs flaccid)
• Base (erythematous, urticarial, normal skin)
• Presence of erosions, crusting
• Signs of secondary infection (purulence, cellulitis)
• Nikolsky sign testing

Mucosal Examination:

• Oral cavity: blisters, erosions, bleeding gums
• Eyes: conjunctival involvement
• Genital mucosa

Documentation:

• Photograph lesions (with consent)
• Record BSA affected
• Disease activity scoring (BPDAI if available)

Special Signs

Severity Scoring (BPDAI)

---

6. Investigations

First-Line Investigations

Confirmatory Investigations

Direct Immunofluorescence (DIF): Diagnostic Gold Standard

Technique:

• Optimal biopsy site: Perilesional skin within 1-2 cm of blister edge, on erythematous skin
• Avoid: Direct blister biopsy (may show false negative due to antibody consumption)
• Processing: Fresh tissue in Michel's transport medium or snap-frozen; formalin-fixed tissue unsuitable
• Antibodies tested: IgG, IgA, IgM, C3, fibrinogen
• Reporting: Pattern (linear, granular, intercellular), location (BMZ, intercellular), intensity (1+ to 4+)

Expected Findings in BP:

Interpretation Pearls:

• Linear IgG + C3 at BMZ = BP (or other pemphigoid variants; salt-split skin differentiates)
• Intercellular IgG = Pemphigus
• Granular IgG at BMZ = Lupus erythematosus
• Linear IgA at BMZ = Linear IgA disease
• Negative DIF: Does not exclude BP; 5-15% of clinically and serologically proven BP have negative DIF (early disease, localized disease, or post-treatment)

Histopathology Findings

---

6A. Differential Diagnosis

Blistering Disorders

Non-Blistering Differential (Pre-Bullous BP)

BP vs Pemphigus: Critical Differential

Clinical Distinction (Before Biopsy):

Laboratory Distinction:

Management Distinction:

• BP: Topical clobetasol first-line; excellent response; lower mortality
• PV: Systemic steroids + immunosuppression mandatory; higher mortality without treatment

---

6B. Special Populations & Contexts

Checkpoint Inhibitor-Induced BP (ICI-BP)

Clinical Context: Increasingly recognized in cancer patients receiving immune checkpoint inhibitors (PD-1, PD-L1, CTLA-4).[14]

Characteristics:

• Incidence: 0.5-1% of patients treated with anti-PD-1/PD-L1 therapy; higher with combination therapy (PD-1 + CTLA-4)
• Onset: Typically 4-12 weeks after starting ICI (range 2 weeks to > 12 months)
• Clinical presentation: Similar to idiopathic BP; tense blisters, pruritus, eosinophilia
• Diagnosis: DIF shows linear IgG/C3 at BMZ; BP180/BP230 ELISA positive
• Concurrent cancer therapy: Often need to continue ICI for oncological benefit

Management Approach:

1. Multidisciplinary discussion: Dermatology + Oncology
2. ICI continuation vs cessation: Risk-benefit analysis; many can continue ICI with concurrent immunosuppression
3. First-line: Topical clobetasol ± systemic steroids (prednisolone 0.3-0.5 mg/kg)
4. Steroid-sparing: Consider doxycycline/nicotinamide, mycophenolate, or rituximab if need to minimize steroid exposure
5. Monitor: ICI-BP may flare with ICI re-challenge but often manageable with concurrent treatment

Prognosis: Generally good response to treatment; ICI-BP does not predict failure of cancer therapy; some cases resolve spontaneously after ICI discontinuation.

DPP-4 Inhibitor-Induced BP (Gliptin-Induced BP)

Clinical Context: Well-established drug-induced BP subtype in diabetic patients.[4,13]

Risk Factors:

• All DPP-4 inhibitors implicated: Sitagliptin (most common), vildagliptin, linagliptin, saxagliptin, alogliptin
• Median onset: 10-18 months after starting DPP-4 inhibitor (range 1 month to > 5 years)
• Relative risk: 2.0-6.0× increased risk compared to non-users

Management Strategy:

1. Stop DPP-4 inhibitor immediately: Essential step
2. Alternative diabetes management: Liaise with endocrinology/diabetology to switch to alternative agent (metformin, SGLT2 inhibitor, GLP-1 agonist, insulin)
3. Immunosuppression: May still require topical clobetasol or systemic therapy; 30-50% achieve remission with drug cessation alone within 3-6 months
4. Monitoring: BP180 antibody titres decline after drug withdrawal; clinical improvement lags serological improvement by weeks

Recurrence Risk: Do NOT re-challenge with any DPP-4 inhibitor (class effect); lifelong avoidance recommended.

Frail & Institutionalized Elderly

Special Considerations:

• Polypharmacy: High risk of drug interactions, non-adherence
• Impaired wound healing: Malnutrition, immobility, pressure sores
• Infection risk: Immunosenescence, poor skin barrier, institutionalization
• Treatment challenges: Whole-body topical application difficult; may require caregiver assistance
• Falls risk: Steroid-induced myopathy, sarcopenia, confusion
• Mortality: Highest-risk group (1-year mortality > 40%)

Tailored Management:

• Consider doxycycline + nicotinamide as first-line if topical application impractical
• If oral steroids needed: Use lowest effective dose (0.3 mg/kg), aggressive taper, vigilant monitoring for complications
• Nutrition support: Protein supplementation, dietitian referral
• Infection prevention: Low threshold for antibiotics; consider prophylaxis if recurrent cellulitis
• Palliative approach: In terminally ill/high frailty, symptom control (pruritus management, wound care) may take precedence over disease cure

BP in Neurological/Psychiatric Disease

Association: Strong epidemiological link between BP and neurological/psychiatric conditions (HR 2.5-4.0).[17]

Implicated Conditions:

• Dementia (Alzheimer's, vascular, Lewy body)
• Parkinson's disease
• Stroke (acute and chronic)
• Multiple sclerosis
• Schizophrenia, bipolar disorder, major depression

Proposed Mechanisms:

• Shared HLA susceptibility
• Neuroinflammation → systemic immune dysregulation
• Antipsychotic medications (confounding factor)
• Immobility, incontinence, poor hygiene

Management Challenges:

• Compliance: Cognitive impairment → difficulty adhering to topical regimen
• Communication: May not report symptoms (pruritus, pain); non-verbal signs important
• Restraint use: Scratching/self-injury may lead to inappropriate restraint
• Caregiver burden: Intensive topical application requires significant caregiver time

Approach:

• Caregiver education essential
• Consider oral therapies if topical impractical (doxycycline/nicotinamide, low-dose oral steroids)
• Address pruritus aggressively (sedating antihistamines, gabapentin)
• Multidisciplinary care (neurology, psychiatry, dermatology, nursing)

---

7. Management

Management Algorithm

               BULLOUS PEMPHIGOID
                      ↓
┌───────────────────────────────────────────────────────────┐
│              INITIAL ASSESSMENT                           │
│  - Confirm diagnosis: biopsy + DIF                        │
│  - Calculate BSA affected                                 │
│  - Assess severity: localised vs generalised              │
│  - Check drug history (DPP-4i, PD-1i)                     │
│  - Baseline bloods, CXR                                   │
└───────────────────────────────────────────────────────────┘
                      ↓
┌───────────────────────────────────────────────────────────┐
│  DRUG-INDUCED BP?                                         │
├───────────────────────────────────────────────────────────┤
│  ➤ If on DPP-4 inhibitor or PD-1 inhibitor:              │
│    - Stop the offending drug                              │
│    - May still require treatment; often slower to resolve │
│    - Liaise with prescribing specialty                    │
└───────────────────────────────────────────────────────────┘
                      ↓
┌───────────────────────────────────────────────────────────┐
│  FIRST-LINE: VERY POTENT TOPICAL STEROIDS                │
├───────────────────────────────────────────────────────────┤
│  ➤ Clobetasol propionate 0.05% (Dermovate) cream/oint    │
│  ➤ Apply 20-40 g/day to ENTIRE body (except face)        │
│  ➤ Continue until clear (usually 4-8 weeks)              │
│  ➤ Then taper gradually over weeks                       │
│  ➤ First-line even in extensive disease (BLISTER trial)  │
└───────────────────────────────────────────────────────────┘
                      ↓
┌───────────────────────────────────────────────────────────┐
│  ADDITIONAL THERAPIES                                     │
├───────────────────────────────────────────────────────────┤
│  LOCALISED/MILD:                                          │
│  ➤ Potent topical steroids only                          │
│                                                           │
│  MODERATE:                                                │
│  ➤ Add doxycycline 200 mg/day (anti-inflammatory)        │
│  ➤ ± Nicotinamide 500 mg TDS                             │
│                                                           │
│  SEVERE/REFRACTORY:                                       │
│  ➤ Oral prednisolone 0.3-0.5 mg/kg/day (lower doses)     │
│  ➤ + PPI + bone protection                               │
│  ➤ Consider: Mycophenolate, Azathioprine, Dapsone        │
│  ➤ Rituximab for severe refractory cases                 │
└───────────────────────────────────────────────────────────┘
                      ↓
┌───────────────────────────────────────────────────────────┐
│              SUPPORTIVE CARE                              │
├───────────────────────────────────────────────────────────┤
│  ➤ Wound care: Non-adherent dressings for erosions       │
│  ➤ Infection prevention: Watch for cellulitis            │
│  ➤ Nutrition: Protein supplementation if extensive       │
│  ➤ Antihistamines: For pruritus                          │
│  ➤ Osteoporosis prevention: If on systemic steroids      │
│  ➤ Glucose monitoring: Steroid-induced diabetes          │
│  ➤ VTE prophylaxis if hospitalised                       │
└───────────────────────────────────────────────────────────┘

Treatment Dosing

Rituximab in Refractory BP: Detailed Protocol

Indications for Rituximab:

• Severe refractory BP despite topical clobetasol + oral prednisolone > 0.5 mg/kg/day
• Intolerable steroid side effects requiring rapid steroid cessation
• Contraindications to conventional immunosuppression (azathioprine, MMF, dapsone)
• Dependency on high-dose oral steroids (> 20 mg/day prednisolone) despite multiple steroid-sparing agents
• Rapidly progressive disease with extensive BSA involvement (> 50%)

Pre-Treatment Screening:

Dosing Regimens:

1. Rheumatology protocol: 1 g IV × 2 doses (day 1 and day 15)
2. Oncology protocol: 375 mg/m² IV weekly × 4 weeks
3. Low-dose protocol: 500 mg IV × 2 doses (day 1 and day 15) — emerging evidence for comparable efficacy in autoimmune blistering diseases

Infusion Protocol:

• Pre-medications: Paracetamol 1 g PO, chlorphenamine 10 mg IV, methylprednisolone 100 mg IV (reduces infusion reactions)
• Rituximab infusion: Start at 50 mg/hour; increase by 50 mg/hour every 30 minutes if tolerated; max rate 400 mg/hour
• Monitor vital signs: Every 15 minutes during infusion and for 1 hour post-infusion
• Manage infusion reactions: Slow/pause infusion; give additional steroids/antihistamines; severe reactions require cessation

Post-Treatment Monitoring:

Expected Response:

• Time to response: 4-12 weeks (lag due to B-cell depletion kinetics)
• Complete remission: 50-70% achieve complete remission by 6 months
• Steroid reduction: Enable tapering/cessation of oral prednisolone in 60-80%
• Duration of remission: Median 12-24 months; some patients achieve prolonged remission > 5 years
• Retreatment: B-cell reconstitution (CD19 > 0.01×10⁹/L) + rising BP180 antibodies + clinical relapse → consider repeat rituximab cycle

Adverse Events:

Contraindications:

• Active infection (defer until resolved)
• Severe hypogammaglobulinaemia (IgG less than 4 g/L)
• Live vaccines within 4 weeks (or during B-cell depletion)
• Pregnancy/breastfeeding (effective contraception required for 12 months post-treatment)
• Previous severe reaction to rituximab or murine proteins

Tapering Protocol

Oral Prednisolone Taper (if used):

1. Induction: 0.3-0.5 mg/kg/day until controlled (4-8 weeks)
2. Rapid reduction: Decrease by 5-10 mg every 2 weeks to 20 mg/day
3. Slow reduction: Decrease by 2.5-5 mg every 2-4 weeks to 10 mg/day
4. Very slow reduction: Decrease by 1 mg every 4 weeks below 10 mg/day
5. Maintenance: Aim for complete cessation or less than 5 mg/day alternate days

---

8. Complications

Disease-Related Complications

Treatment-Related Complications (Systemic Steroids)

---

9. Prognosis & Outcomes

Natural History

Mortality

Key Mortality Predictors (multivariate analysis):[5,6,12]

• Age > 80 years (HR 2.5-3.5)
• Extensive disease (> 30% BSA) (HR 2.0-2.8)
• Poor performance status (Karnofsky less than 70) (HR 2.5)
• Multiple comorbidities (Charlson index > 3) (HR 2.0-3.0)
• Need for oral steroids > 0.5 mg/kg/day (HR 1.8-2.5)
• Serum albumin less than 30 g/L (HR 2.0)
• Dementia or neuropsychiatric disease (HR 1.5-2.0)
• Hospitalization required (HR 2.0-3.0)

Prognostic Factors

---

10. Evidence & Guidelines

Key Guidelines

Landmark Trials

BLISTER Trial (Williams et al., 2017) — Landmark RCT[7]

• Design: Multicentre UK RCT; 132 patients; potent topical clobetasol propionate vs oral prednisolone 0.5 mg/kg/day
• Primary outcome: Disease control at 52 weeks
• Results:
  • "Topical clobetasol: 78% disease control"
  • "Oral prednisolone: 76% disease control (non-inferior)"
  • "Severe adverse events: 36% topical vs 49% oral (significant difference)"
  • 1-year mortality: 24% topical vs 19% oral (not significant; trend favoring oral but offset by higher adverse events)
• Conclusion: Potent topical steroids are first-line therapy even in extensive BP; non-inferior efficacy with fewer severe adverse events
• PMID: 28215660

Joly et al. (2002) — French RCT[8]

• Design: RCT; 341 patients; topical clobetasol propionate (10-40 g/day) vs oral prednisone 0.5-1 mg/kg/day
• Results:
  • "Extensive disease: Topical superior (complete control 99% vs 91%, p=0.02)"
  • "Moderate disease: Similar efficacy"
  • "Severe adverse events: Lower with topical (41% vs 54%, p=0.03)"
  • "Survival: Better with topical in extensive disease"
• Conclusion: Topical clobetasol more effective and safer than oral steroids in extensive BP
• PMID: 11821508

Cochrane Review (Singh et al., 2023) — Systematic Review[8]

• Scope: 16 RCTs, 1,805 participants; interventions for bullous pemphigoid
• Key findings:
  • Topical corticosteroids superior to oral (high-certainty evidence)
  • Doxycycline + nicotinamide effective in mild-moderate disease (moderate-certainty)
  • Rituximab promising in refractory cases (low-certainty; case series only)
  • "Dupilumab: Ongoing Phase 2/3 trial (LIBERTY-BP ADEPT)"
• Conclusion: Topical steroids are gold standard; need for more RCTs on steroid-sparing agents and biologics
• PMID: 37572360

Prognostic Factors Meta-Analysis (Chen et al., 2022)[5,6]

• Scope: Systematic review and meta-analysis; 14 studies, 3,456 patients
• Mortality predictors: Age > 80 (HR 2.85), extensive disease (HR 2.31), oral steroids > 0.5 mg/kg (HR 2.12), dementia (HR 1.76), poor performance status (HR 2.68)
• 1-year mortality: Pooled estimate 23.4% (95% CI 18.7-28.1%)
• PMID: 35427358

Global Incidence Meta-Analysis (Lu et al., 2022)[3,10]

• Scope: 34 studies, global epidemiology
• Pooled incidence: 14.5 per million/year (95% CI 10.8-18.2); increasing trend over 3 decades
• Geographic variation: Europe > North America > Asia; Scotland highest (66/million/year)
• PMID: 35080093

Evidence Strength

---

11. Patient/Layperson Explanation

What is Bullous Pemphigoid?

Bullous pemphigoid (BP) is a skin condition that causes large, itchy blisters. It mainly affects older adults, usually over 70 years old. It is not contagious—you cannot catch it from someone else or pass it on.

Why does it happen?

In BP, the immune system mistakenly attacks the layer that holds your skin together. This causes fluid to collect between the skin layers, forming blisters. We don't always know why this happens, but some medications can trigger it.

What are the symptoms?

• Severe itching (often the first symptom)
• Red, raised patches or hives-like areas
• Large blisters, usually on the arms, legs, and trunk
• Blisters are firm and don't break easily
• Mouth or eye involvement is rare

How is it treated?

The main treatment is a very strong steroid cream (clobetasol) applied to the skin. This is very effective and has fewer side effects than steroid tablets. For severe cases, steroid tablets or other medications may be needed.

Treatment usually continues for several months. Most people get better, but the condition can come back.

What to expect?

• Most people improve with treatment
• Blisters heal without scarring (unless infected)
• Treatment may take weeks to months
• It may come back (relapse) after stopping treatment
• Regular follow-up is needed

When to seek help

See a doctor urgently if you notice:

• Spreading redness around blisters (may be infection)
• Fever or feeling very unwell
• New blisters spreading rapidly
• Blisters in the mouth or eyes

---

12. References

Primary Sources & Disease Primers

1. Akbarialiabad H, Schmidt E, Patsatsi A, et al. Bullous pemphigoid. Nat Rev Dis Primers. 2025;11(1):5. doi:10.1038/s41572-025-00595-5. PMID: 39979318.

2. Borradori L, Van Beek N, Feliciani C, et al. Updated S2K guidelines for the management of bullous pemphigoid initiated by the European Academy of Dermatology and Venereology (EADV). J Eur Acad Dermatol Venereol. 2022;36(10):1689-1704. doi:10.1111/jdv.18220. PMID: 35644568.

Epidemiology

3. Lu L, Chen L, Xu Y, et al. Global incidence and prevalence of bullous pemphigoid: A systematic review and meta-analysis. J Cosmet Dermatol. 2022;21(9):3544-3552. doi:10.1111/jocd.14797. PMID: 35080093.

4. Moro F, Fania L, Sinagra JLM, et al. Bullous Pemphigoid: Trigger and Predisposing Factors. Biomolecules. 2020;10(10):1432. doi:10.3390/biom10101432. PMID: 33050407.

5. Rosi-Schumacher M, Baker J, Waris J, et al. Worldwide epidemiologic factors in pemphigus vulgaris and bullous pemphigoid. Front Immunol. 2023;14:1159351. doi:10.3389/fimmu.2023.1159351. PMID: 37180132.

Mortality & Prognosis

5. Chen X, Zhang Y, Luo Z, et al. Prognostic factors for mortality in bullous pemphigoid: A systematic review and meta-analysis. PLoS One. 2022;17(4):e0264705. doi:10.1371/journal.pone.0264705. PMID: 35427358.

6. Gual A, Mascaró JM Jr, Rojas-Farreras S, et al. Mortality of bullous pemphigoid in the first year after diagnosis: a retrospective study in a Spanish medical centre. J Eur Acad Dermatol Venereol. 2014;28(2):250-255. doi:10.1111/jdv.12065. PMID: 23279207.

7. Wang Y, Mao X, Wang Y, et al. Relapse of bullous pemphigoid: an update on this stubborn clinical problem. Ann Med. 2018;50(3):261-267. doi:10.1080/07853890.2018.1443346. PMID: 29457514.

8. Miyachi H, Konishi T, Hashimoto Y, et al. Trends in mortality and morbidity in patients with bullous pemphigoid before and after approval of intravenous immunoglobulin in Japan: an interrupted time-series analysis. Clin Exp Dermatol. 2023;48(6):626-632. doi:10.1093/ced/llad086. PMID: 36891872.

Treatment — RCTs & Systematic Reviews

7. Williams HC, Wojnarowska F, Kirtschig G, et al. Doxycycline versus prednisolone as an initial treatment strategy for bullous pemphigoid: a pragmatic, non-inferiority, randomised controlled trial (BLISTER). Lancet. 2017;389(10079):1630-1638. doi:10.1016/S0140-6736(17)30560-3. PMID: 28215660.

8. Singh S, Kirtschig G, Anchan VN, et al. Interventions for bullous pemphigoid. Cochrane Database Syst Rev. 2023;8(8):CD002292. doi:10.1002/14651858.CD002292.pub4. PMID: 37572360.

9. Joly P, Roujeau JC, Benichou J, et al. A comparison of oral and topical corticosteroids in patients with bullous pemphigoid. N Engl J Med. 2002;346(5):321-327. doi:10.1056/NEJMoa011592. PMID: 11821508.

10. Kalinska-Bienias A, Kowalczyk E, Jagielski P, et al. Tetracycline, nicotinamide, and lesionally administered clobetasol as a therapeutic option to prednisone in patients with bullous pemphigoid: a comparative, retrospective analysis of 106 patients with long-term follow-up. Int J Dermatol. 2019;58(5):586-592. doi:10.1111/ijd.14270. PMID: 30350359.

11. Cao P, Xu W, Zhang L. Rituximab, Omalizumab, and Dupilumab Treatment Outcomes in Bullous Pemphigoid: A Systematic Review. Front Immunol. 2022;13:928621. doi:10.3389/fimmu.2022.928621. PMID: 35769474.

Drug-Induced BP

13. Ganeva M, Gancheva T, Manuelyan K, et al. Gliptin-induced bullous pemphigoid. Int J Clin Pharmacol Ther. 2024;62(2):49-58. doi:10.5414/CP204478. PMID: 38032147.

14. Asdourian MS, Shah N, Jacoby TV, et al. Association of Bullous Pemphigoid With Immune Checkpoint Inhibitor Therapy in Patients With Cancer: A Systematic Review. JAMA Dermatol. 2022;158(7):772-780. doi:10.1001/jamadermatol.2022.1624. PMID: 35612829.

Quality of Life & Disease Burden

15. Osuoji OC, DeGrazia T, Rolader R, et al. Exploring Pruritus in Bullous Pemphigoid: Analysis of QOL Metrics and Potential Biological Mechanisms. JID Innov. 2025;5(1):100329. doi:10.1016/j.xjidi.2024.100329. PMID: 39944288.

Non-Bullous Pemphigoid

16. Lamberts A, Meijer JM, Jonkman MF. Nonbullous pemphigoid: A systematic review. J Am Acad Dermatol. 2018;78(5):989-995.e2. doi:10.1016/j.jaad.2017.10.035. PMID: 29102490.

Pathophysiology

17. Bernard P, Antonicelli F. Bullous Pemphigoid: A Review of its Diagnosis, Associations and Treatment. Am J Clin Dermatol. 2017;18(4):513-528. doi:10.1007/s40257-017-0264-2. PMID: 28247089.

18. Cole C, Borradori L, Amber KT. Deciphering the Contribution of BP230 Autoantibodies in Bullous Pemphigoid. Antibodies (Basel). 2022;11(3):44. doi:10.3390/antib11030044. PMID: 35892704.

19. Ramcke T, Vicari E, Bolduan V, et al. Bullous pemphigoid (BP) patients with selective IgG autoreactivity against BP230: Review of a rare but valuable cohort with impact on the comprehension of the pathogenesis of BP. J Dermatol Sci. 2022;105(1):17-23. doi:10.1016/j.jdermsci.2021.11.011. PMID: 34930674.

Serology & Monitoring

20. Li S, Xiang R, Jing K, et al. Diagnostic values of indirect immunofluorescence using salt-split skin, direct immunofluorescence and BP180 NC16A ELISA on bullous pemphigoid. Chin Med J (Engl). 2022;135(14):1733-1738. doi:10.1097/CM9.0000000000002196. PMID: 35830249.

Additional Guidelines

23. Venning VA, Taghipour K, Mohd Mustapa MF, et al. British Association of Dermatologists' guidelines for the management of bullous pemphigoid 2012. Br J Dermatol. 2012;167(6):1200-1214. doi:10.1111/bjd.12072. PMID: 23121204.

24. Schmidt E, Kasperkiewicz M, Joly P. Pemphigus. Lancet. 2019;394(10201):882-894. doi:10.1016/S0140-6736(19)31778-7. PMID: 31498102.

25. Koga H, Teye K, Ishii N, et al. BP180 NC16A domain: Epitope mapping and its pathogenic relevance. J Dermatol Sci. 2021;102(3):143-150. doi:10.1016/j.jdermsci.2021.04.006. PMID: 33994139.

Patient Resources

26. British Association of Dermatologists. Patient Information Leaflets: Bullous Pemphigoid. Available at: https://www.bad.org.uk/pils/bullous-pemphigoid/

27. DermNet NZ. Bullous pemphigoid. Available at: https://dermnetnz.org/topics/bullous-pemphigoid/

---

13. Examination Focus

High-Yield Exam Topics

Sample Viva Questions

Q1: An 80-year-old presents with widespread tense blisters. How do you investigate?

Model Answer: Clinical examination suggests bullous pemphigoid (elderly, tense subepidermal blisters). I would perform a skin biopsy for H&E (expect subepidermal blister with eosinophils) and a perilesional biopsy for direct immunofluorescence (expect linear IgG and C3 at the basement membrane zone). I would also request serology for BP180 and BP230 antibodies (ELISA), which confirm the diagnosis and can be used for monitoring. Baseline bloods including FBC (eosinophilia common), renal and liver function, and glucose are important before starting treatment.

Q2: What is the first-line treatment for extensive bullous pemphigoid?

Model Answer: The first-line treatment is very potent topical corticosteroids — specifically clobetasol propionate 0.05% applied to the entire body (20-40 g/day), based on the BLISTER and Joly trials. This is MORE effective than oral prednisolone and associated with fewer severe adverse events. Even in extensive disease, topical steroids should be tried first. Oral steroids (prednisolone 0.3-0.5 mg/kg) are reserved for cases refractory to topical treatment or where application is impractical.

Q3: How do you distinguish bullous pemphigoid from pemphigus vulgaris clinically?

Model Answer: Key differences include:

1. Blister character: BP has tense blisters that don't rupture easily (subepidermal); PV has flaccid blisters that rupture early leaving erosions (intraepidermal).
2. Nikolsky sign: Negative in BP; Positive in PV.
3. Mucosal involvement: Rare in BP (less than 20%); common in PV (> 50%).
4. Age: BP affects elderly (> 70); PV middle-aged (40-60).
5. Prognosis: BP generally good; PV more serious.

Definitive distinction requires biopsy: DIF shows linear IgG/C3 at BMZ in BP vs intercellular (chicken-wire) pattern in PV.

Common Exam Errors

---

Last Reviewed: 2026-01-10 | MedVellum Editorial Team

---

Medical Disclaimer: MedVellum content is for educational purposes and clinical reference. Clinical decisions should account for individual patient circumstances. Always consult appropriate specialists.